Answers are grounded in this paper and cite their sources.
Mesenchymal stromal cell (MSC) therapy is being investigated for hepatic and renal disorders, but biochemical changes do not necessarily establish organ regeneration or clinical benefit. This non-exhaustive narrative review evaluates direct MSC interventions and six blood analytes: alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, urea, and creatinine. PubMed-indexed English-language studies published from 2000 through 11 October 2026 were considered when complete texts and relevant findings were accessible; reviews and methodological sources provide background. Evidence is interpreted by species, disease, specimen, cell product, comparison type, and follow-up. Proposed mechanisms include paracrine signaling, immunomodulation, and host responses to administered cells, with varying experimental support. Selected preclinical studies report biochemical improvements, whereas human findings are heterogeneous. Serum total-protein responses are limited and product-dependent, and direct serum-urea evidence is mainly preclinical. The ACT-AKI trial found no acceleration of creatinine-defined recovery, while a randomized cirrhosis follow-up showed a within-arm bilirubin decline without a significant between-group difference. Urea nitrogen, albumin, urinary protein, and filtration outcomes are distinguished from the specified concentrations. Findings are synthesized descriptively, with explicit source uncertainties. Standardized cell characterization and controlled trials combining biochemical, histological, and functional outcomes are needed to assess durable clinical benefit.
No takes yet. Share an insight, caveat, or question.
Altaeva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: